The FDA has said it cannot approve Summit Therapeutics and Akeso's PD-1xVEGF inhibitor ivonescimab, delaying a drug that is ...

Asundexian has been approved by the FDA under the Sunharbo brand name for use in combination with antiplatelet therapy to ...

Hims & Hers is also offering compounded formulations of other unapproved peptides, including sermorelin, which some people ...

The FDA has ordered all GLP-1 receptor agonist manufacturers to add a warning to the label of their products for a rare eye ...

UK-based startup Oyster Therapeutics has raised $60 million in first-round financing that will be used to advance its tau ...

Theramex, a London, UK-based specialty pharma company focusing on women's health, is changing hands in a deal reportedly ...

Patients with muscle-invasive bladder cancer can now receive NHS treatment with a regimen of MSD's Keytruda and Astellas' ...

Amazon Web Services (AWS) has committed $100 million in AI and cloud technology capacity to support the building of health ...

Specifically, the MHRA approved Zynyz as a first- and second-line treatment for adults with advanced squamous cell carcinoma ...

The takeover deal – worth up to $1.15 billion including $550 million in upfront cash – will upgrade the Dutch biotech's ...

Novo has raised its financial guidance for 2026 on the back of rising sales of its oral weight-loss therapy Wegovy, which ...

Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies Zepbound and Foundayo sold ...